Eli Lilly, Incyte's Olumiant notches atopic dermatitis trial win by Kyle Blankenship Monday, January 27, 2020 Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?
Lilly inks $1.1B Dermira deal as biopharma M&A gets underway by Arlene Weintraub Friday, January 10, 2020 Eli Lilly's $1.1 billion Dermira bid is smart, some analysts say, because it brings in both a marketed drug and a phase 3 atopic dermatitis asset.
Can Dupixent steal half of a $21B eczema market? Not so fast by Arlene Weintraub Wednesday, December 11, 2019 Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.
Condé Nast's new digital buying plan scores with pharma by Beth Snyder Bulik Monday, December 16, 2019 Pharma companies jump on board Condé Nast’s upfront buying program in droves, locking in digital buys for 2020.
Amgen, GSK advance to #FierceMadness Elite 8 by Beth Snyder Bulik, Carly Helfand Wednesday, March 27, 2019 And then there were eight. The #FierceMadness Elite Eight bracket is set, with six brand-name drugs and two awareness campaigns still in the running.
Dermira taps real patients in first ads for Qbrexza by Beth Snyder Bulik Monday, March 25, 2019 Real patients share their before-and-after scenarios in Dermira’s first ad campaign for excessive sweating treatment Qbrexza.
Dermira and its new reps gear up for impending Qbrexza launch by Beth Snyder Bulik Wednesday, September 5, 2018 Dermira announces details on pricing, sales rep hires and a planned branded advertising campaign for Qbrexza, its treatment for excessive sweating that launches Oct. 1.
